AnaptysBio, Inc. (ANAB)
Largest Insider Buys in Sector
ANAB Stock Price History Chart
ANAB Stock Performance
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable …
Insider Activity of AnaptysBio, Inc.
Over the last 12 months, insiders at AnaptysBio, Inc. have bought $10M and sold $5.59M worth of AnaptysBio, Inc. stock.
On average, over the past 5 years, insiders at AnaptysBio, Inc. have bought $24.14M and sold $6.1M worth of stock each year.
Highest buying activity among insiders over the last 12 months: EcoR1 Capital, LLC (10 percent owner) — $50M.
The last purchase of 273,972 shares for transaction amount of $10M was made by EcoR1 Capital, LLC (10 percent owner) on 2024‑08‑14.
List of Insider Buy and Sell Transactions, AnaptysBio, Inc.
| 2024-09-23 | Sale | Chief Medical Officer | 1,500 0.0054% | $38.67 | $58,005 | -6.54% | ||
| 2024-09-17 | Sale | CHIEF LEGAL OFFICER | 3,780 0.0128% | $38.41 | $145,191 | -10.03% | ||
| 2024-09-16 | Sale | Chief Medical Officer | 2,220 0.0074% | $38.93 | $86,425 | -12.24% | ||
| 2024-09-16 | Sale | CHIEF LEGAL OFFICER | 8,720 0.0297% | $39.82 | $347,270 | -12.24% | ||
| 2024-09-16 | Sale | CHIEF FINANCIAL OFFICER | 12,220 0.0417% | $39.91 | $487,725 | -12.24% | ||
| 2024-08-14 | Sale | Chief Medical Officer | 2,000 0.0088% | $40.00 | $80,000 | 0.00% | ||
| 2024-08-14 | 10 percent owner | 273,972 1.095% | $36.50 | $10M | 0.00% | |||
| 2024-07-18 | Sale | Chief Medical Officer | 1,500 0.0056% | $35.00 | $52,500 | +2.00% | ||
| 2024-07-15 | Sale | director | 10,000 0.0463% | $30.64 | $306,422 | 0.00% | ||
| 2024-06-21 | Sale | director | 1,950 0.007% | $23.17 | $45,182 | +45.75% | ||
| 2024-06-18 | Sale | director | 1,950 0.007% | $23.16 | $45,162 | +52.08% | ||
| 2024-05-22 | Sale | CHIEF FINANCIAL OFFICER | 1,500 0.0052% | $23.72 | $35,580 | +34.96% | ||
| 2024-03-25 | Sale | CEO | 3,000 0.0114% | $21.42 | $64,268 | +22.25% | ||
| 2024-03-22 | Sale | CEO | 145,940 0.5734% | $22.78 | $3.33M | +18.87% | ||
| 2024-02-16 | Sale | CHIEF LEGAL OFFICER | 5,000 0.0195% | $25.00 | $125,000 | +5.77% | ||
| 2024-01-30 | Sale | CHIEF FINANCIAL OFFICER | 3,065 0.0114% | $23.63 | $72,425 | +4.88% | ||
| 2024-01-08 | Sale | CEO | 6,866 0.0251% | $21.81 | $149,747 | +8.64% | ||
| 2024-01-08 | Sale | Chief Medical Officer | 2,554 0.0093% | $21.81 | $55,703 | +8.64% | ||
| 2024-01-08 | Sale | Chief Financial Officer | 2,180 0.008% | $21.81 | $47,546 | +8.64% | ||
| 2024-01-08 | Sale | Chief Legal Officer | 2,305 0.0084% | $21.81 | $50,272 | +8.64% |
Insider Historical Profitability
| EcoR1 Capital, LLC | 10 percent owner | 7794996 25.8114% | $22.50 | 10 | 0 | +15.76% |
| NODELMAN OLEG | 7521024 24.9042% | $22.50 | 1 | 1 | +12.85% | |
| Novo Holdings A/S | 10 percent owner | 1936604 6.4126% | $22.50 | 1 | 8 | +58.88% |
| Topper James N | 1045031 3.4604% | $22.50 | 1 | 0 | +58.88% | |
| Frazier Healthcare V, LP | 10 percent owner | 311291 1.0308% | $22.50 | 1 | 0 | +58.88% |
Institutional Investor Ownership
| Ecor1 Capital Llc | $169.37M | 27.53 | 7.52M | 0% | +$0 | 1.19 | |
| BlackRock | $38.74M | 6.3 | 1.72M | -4.43% | -$1.8M | <0.01 | |
| The Vanguard Group | $30.49M | 4.96 | 1.35M | -1.89% | -$588,042.23 | <0.01 | |
| Tang Capital Management, LLC | $29.97M | 4.87 | 1.33M | -31.77% | -$13.96M | 0.11 | |
| Boxer Capital, LLC | $29.28M | 4.76 | 1.3M | 0% | +$0 | 0.6 |